Do analysts prefer MDXH or RLYB?

MDxHealth presently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, MDXH or RLYB?

Rallybio has lower revenue, but higher earnings than MDxHealth. Rallybio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MDxHealth $107.88M 0.37 -$33.52M -$0.65 N/A Rallybio $860K 104.90 -$8.98M -$4.34 N/A

Is MDXH or RLYB more profitable?

MDxHealth has a net margin of -33.46% compared to Rallybio's net margin of -911.07%. MDxHealth's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -23.38% Rallybio -911.07% -40.53% -38.13%

Does the media refer more to MDXH or RLYB?

In the previous week, MDxHealth had 8 more articles in the media than Rallybio. MarketBeat recorded 11 mentions for MDxHealth and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.44 beat MDxHealth's score of 0.89 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MDXH or GANX?

In the previous week, MDxHealth had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for MDxHealth and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat MDxHealth's score of 0.89 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SERA or MDXH?

In the previous week, MDxHealth had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for MDxHealth and 8 mentions for Sera Prognostics. MDxHealth's average media sentiment score of 0.89 beat Sera Prognostics' score of -0.16 indicating that MDxHealth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MDXH or TELO?

MDxHealth currently has a consensus price target of $2.83, suggesting a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts plainly believe MDxHealth is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer MDXH or TELO?

In the previous week, MDxHealth had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 11 mentions for MDxHealth and 7 mentions for Telomir Pharmaceuticals. MDxHealth's average media sentiment score of 0.89 beat Telomir Pharmaceuticals' score of 0.01 indicating that MDxHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to MDXH or ATRA?

In the previous week, MDxHealth had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 11 mentions for MDxHealth and 7 mentions for Atara Biotherapeutics. MDxHealth's average media sentiment score of 0.89 beat Atara Biotherapeutics' score of -0.33 indicating that MDxHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Trading of MDxHealth was halted at 11:36 AM EST due to "LULD Pause".

MDxHealth (MDXH) Competitors

$0.81 +0.35 (+74.89%)

Closing price 04:00 PM Eastern

Extended Trading

$0.71 -0.09 (-11.63%)

As of 07:59 PM Eastern

Compare

MDXH vs. RLYB, GANX, SERA, TELO, and ATRA

Should you buy MDxHealth stock or one of its competitors? MDxHealth's main competitors and comparable companies include Rallybio (RLYB), Gain Therapeutics (GANX), Sera Prognostics (SERA), Telomir Pharmaceuticals (TELO), and Atara Biotherapeutics (ATRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MDxHealth compare to Rallybio?

MDxHealth (NASDAQ:MDXH) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Rallybio has lower revenue, but higher earnings than MDxHealth. Rallybio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Rallybio	$860K	104.90	-$8.98M	-$4.34	N/A

90.3% of Rallybio shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MDxHealth has a net margin of -33.46% compared to Rallybio's net margin of -911.07%. MDxHealth's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
Rallybio	-911.07%	-40.53%	-38.13%

MDxHealth has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market.

In the previous week, MDxHealth had 8 more articles in the media than Rallybio. MarketBeat recorded 11 mentions for MDxHealth and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.44 beat MDxHealth's score of 0.89 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MDxHealth presently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MDxHealth beats Rallybio on 11 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Gain Therapeutics?

MDxHealth (NASDAQ:MDXH) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

MDxHealth presently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

12.0% of Gain Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MDxHealth has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
Gain Therapeutics	N/A	-161.59%	-118.36%

In the previous week, MDxHealth had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for MDxHealth and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat MDxHealth's score of 0.89 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has lower revenue, but higher earnings than MDxHealth. Gain Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

Summary

Gain Therapeutics beats MDxHealth on 10 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Sera Prognostics has higher earnings, but lower revenue than MDxHealth. Sera Prognostics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A

Sera Prognostics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 180.61%. MDxHealth has a consensus price target of $2.83, suggesting a potential upside of 250.66%. Given MDxHealth's higher possible upside, analysts clearly believe MDxHealth is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

54.6% of Sera Prognostics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, MDxHealth had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for MDxHealth and 8 mentions for Sera Prognostics. MDxHealth's average media sentiment score of 0.89 beat Sera Prognostics' score of -0.16 indicating that MDxHealth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MDxHealth has a net margin of -33.46% compared to Sera Prognostics' net margin of -47,475.72%. MDxHealth's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
MDxHealth	-33.46%	N/A	-23.38%

Summary

MDxHealth beats Sera Prognostics on 10 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Telomir Pharmaceuticals?

MDxHealth (NASDAQ:MDXH) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

MDxHealth has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

In the previous week, MDxHealth had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 11 mentions for MDxHealth and 7 mentions for Telomir Pharmaceuticals. MDxHealth's average media sentiment score of 0.89 beat Telomir Pharmaceuticals' score of 0.01 indicating that MDxHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

MDxHealth currently has a consensus price target of $2.83, suggesting a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts plainly believe MDxHealth is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has lower revenue, but higher earnings than MDxHealth. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Telomir Pharmaceuticals has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
Telomir Pharmaceuticals	N/A	-98.73%	-85.85%

Summary

MDxHealth beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does MDxHealth compare to Atara Biotherapeutics?

MDxHealth (NASDAQ:MDXH) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

MDxHealth has a net margin of -33.46% compared to Atara Biotherapeutics' net margin of -269.42%. MDxHealth's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

MDxHealth has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than MDxHealth. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Atara Biotherapeutics	$120.77M	0.60	$32.69M	-$0.67	N/A

MDxHealth currently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 17.43%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts plainly believe MDxHealth is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MDxHealth had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 11 mentions for MDxHealth and 7 mentions for Atara Biotherapeutics. MDxHealth's average media sentiment score of 0.89 beat Atara Biotherapeutics' score of -0.33 indicating that MDxHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.9% of Atara Biotherapeutics shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MDxHealth beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

Get MDxHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXH vs. The Competition

Export

Metric	MDxHealth	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.87M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.12	10.67	269.06	25.28
Price / Sales	0.37	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-3.37	16.78	12.91	6.24
Net Income	-$33.52M	-$13.32M	$3.45B	$347.60M
7 Day Performance	75.27%	1.74%	1.12%	1.07%
1 Month Performance	94.65%	1.60%	1.79%	1.03%
1 Year Performance	-71.55%	56.43%	67.69%	20.77%

MDxHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXH MDxHealth	2.4945 of 5 stars	$0.81 +74.9%	$2.83 +250.7%	-83.2%	$22.87M	$107.88M	N/A	300	Trending News Earnings Report Analyst Forecast Gap Up Trading Halted High Trading Volume
RLYB Rallybio	2.0739 of 5 stars	$16.38 -1.4%	N/A	+296.0%	$88.21M	$860K	N/A	40	News Coverage Positive News Short Interest Decrease
GANX Gain Therapeutics	2.8247 of 5 stars	$2.06 +16.4%	$7.50 +264.1%	+39.4%	$87.87M	N/A	N/A	20	Positive News Earnings Report Analyst Forecast High Trading Volume
SERA Sera Prognostics	2.6686 of 5 stars	$1.99 -1.0%	$5.50 +176.4%	-12.6%	$78.71M	$80K	N/A	120	News Coverage Earnings Report Gap Up
TELO Telomir Pharmaceuticals	0.5272 of 5 stars	$1.13 -3.4%	N/A	-34.4%	$77.72M	N/A	N/A	1	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXH) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MDxHealth (MDXH) Competitors

MDXH vs. RLYB, GANX, SERA, TELO, and ATRA

How does MDxHealth compare to Rallybio?

Summary

How does MDxHealth compare to Gain Therapeutics?

Summary

How does MDxHealth compare to Sera Prognostics?

Summary

How does MDxHealth compare to Telomir Pharmaceuticals?

Summary

How does MDxHealth compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MDxHealth (MDXH) Competitors

MDXH vs. RLYB, GANX, SERA, TELO, and ATRA

How does MDxHealth compare to Rallybio?

Which has stronger earnings and valuation, MDXH or RLYB?

Do insiders and institutionals believe in MDXH or RLYB?

Is MDXH or RLYB more profitable?

Which has more risk and volatility, MDXH or RLYB?

Does the media refer more to MDXH or RLYB?

Do analysts prefer MDXH or RLYB?

Summary

How does MDxHealth compare to Gain Therapeutics?

Do analysts recommend MDXH or GANX?

Do insiders and institutionals believe in MDXH or GANX?

Which has more volatility and risk, MDXH or GANX?

Is MDXH or GANX more profitable?

Does the media refer more to MDXH or GANX?

Which has better earnings and valuation, MDXH or GANX?

Summary

How does MDxHealth compare to Sera Prognostics?

Which has better valuation & earnings, SERA or MDXH?

Which has more volatility & risk, SERA or MDXH?

Do analysts rate SERA or MDXH?

Do institutionals and insiders hold more shares of SERA or MDXH?

Does the media prefer SERA or MDXH?

Is SERA or MDXH more profitable?

Summary

How does MDxHealth compare to Telomir Pharmaceuticals?

Which has more risk & volatility, MDXH or TELO?

Does the media prefer MDXH or TELO?

Do analysts rate MDXH or TELO?

Which has better earnings & valuation, MDXH or TELO?

Is MDXH or TELO more profitable?

Summary

How does MDxHealth compare to Atara Biotherapeutics?

Is MDXH or ATRA more profitable?

Which has more risk & volatility, MDXH or ATRA?

Which has higher valuation & earnings, MDXH or ATRA?

Do analysts rate MDXH or ATRA?

Does the media refer more to MDXH or ATRA?

Do insiders and institutionals believe in MDXH or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools